׳¦׳׳˜

הידעת? הדפדפן שהינך גולש ממנו אינו עדכני

הדפדפן שהינך גולש ממנו אינו עדכני ויתכן שהאתר אינו יעבוד בצורה טובה. הדפדפנים הנתמכים באתר הם:

לחץ על האיקונים למעבר לדף ההורדה של הדפדפן

סגירת חלונית אל תציג בשנית

בסגירת החלונית תועבר/י לאתר מותאם לדפדפן ויתכן כי חלק מהאתר לא יעבוד בצורה מיטבית

Pterygium / Pinguecula

הדפסה דוא

CDR - Center for Drug Repurposing

 

Pterygium (Surfer’s Eye) and Pinguecula are elevated, superficial, external ocular masses that usually form over the conjunctiva. Most pterygia start as a pinguecula, which then extends onto the corneal limbus and frequently beyond. The prevalance of pterygium is as high as 30% in people living in countries close to the equator.

Depending on the size and height of the lesion, ocular surface irritation may occur, causing patients to experience dryness and a foreign body sensation. Sometimes pingueculae and pterygia may become inflamed, further exacerbating these symptoms. Pterygia and pingueculae also create significant cosmetic concern.

 

Existing Treatment

Pterygia and pingueculae are often treated with topical indomethacin (a nonsteroidal anti-inflammatory drug) or steroids to decrease acute inflammation. Patients receiving topical steroids require regular monitoring of intraocular pressure due to an increased risk of glaucoma. The only known cure is surgery, which is often not completely successful and results in very high recurrence rates or permanent damage to the eye surface. However, the Center for Drug Repurposing is now researching a new treatment.

 

New Treatment

Dipyridamole (Persantin) is a drug that was originally introduced in 1959 as an anti-anginal medication and was subsequently found to inhibit platelet aggregation. It has a long history of safe usage. Long-term high-dose studies in mice have demonstrated that it is non-carcinogenic and non-mutagenic. The typical oral daily dose in humans ranges between 200 mg and 400 mg.

 

As can be seen in the first publication on the use of dipyridamole drops for a pterygium “Pterygium: Nonsurgical Treatment Using Topical Dipyridamole - A Case Report”, the outcome was remarkable:

Pterygium #1

Pterygium #2 

Pterygium #3

 

Following numerous successful outcomes of patients treated with ultra-low-dose dipyridamole eye drops for pterygia and pingueculae, the Center for Drug Repurposing has launched a number of projects to advance knowledge about this novel treatment. These include:

  • Formulation studies
  • Stability studies
  • Mechanism of Action studies
  • Optimal dosing studies

 

To support our pioneering research for pterygia (Surfer’s Eye) and pingueculae and thereby speed up the development of new safe and effective treatments, please contact us by email at cdr@ariel.ac.il and we will reply with different funding opportunities. As a supporter you will benefit from early updates about our progress

 

עדכון אחרון ב-חמישי, 28 מאי 2015 11:32
 

 

ברוכים הבאים לאתר אוניברסיטת אריאל בשומרון לכל צורכי הנגישות יש ללחוץ על כפתור הנגישות למעלה